Framework Journal · one stock, one dated entry

Recorded 2026-07-19 · Permanent

Artivion, Inc. AORT

Clears both ethical standards

An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.

In plain words · Artivion, Inc.

The label
Markup

read at $25.06

Artivion, Inc. holds its Markup at $25.06.

PHINPOOPSC
  • PHPhase · the trend structure carries the Markup label
  • INInsiders · no filings inside 60 days, left as found
  • POPositioning · no disclosures inside 60 days, left as found
  • OPOptions · no verdict drawn today, left as found
  • SCScreen · passes the values gate
  • edge confirmed
  • edge broken
  • edge forming

Each arm is one independent read. Conviction is not a single call, it is how many edges converge.

The investor read · the season, not the day

As held on the ledger · 2026-07-19
PhaseMarkup
Quantitative stateThe statistical read favours the sellers, held for 13 days
Price$25.06
Valuation100.24 trailing · 34.81 forward price to earnings
Values screenPASS · score 70.0
Beta1.25

The opportunity · what the numbers say it is worth

Read at
$25.06
100.24 P/E · 34.81 fwd
Our fair value
$29.42
17% discount
Analyst target (avg)
$43.00
+72% to current
Target low $36.00Analyst target rangeTarget high $48.00
▲ current $25.06 · | average target

Price history & projections · where it has been, where the models see it going

$50.6$31.7$12.9TODAY5y agoPROJECTIONAnalyst high$48.00 +134%Analyst avg$43.00 +110%Conservative$29.42 +44%Our fair value$29.42 +44%

The valuation journey · where the price sits against fair value and the Street

Current
$25.06
you are here
Conservative
$29.42
+17%
Analyst avg
$43.00
+72%
Our fair value
$29.42
+17%
Analyst high
$48.00
+92%

Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Revenue growth17.50%
Profit margin2.55%
Debt to equity57.31
Analyst consensusNone · 8 covering

Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.

The values screen, explained · five checks, plain English

This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:

The common standard · AAOIFI
Used by most halal investing apps
✓ PASSES
Our stricter standard · asset-based
The one Titan applies
✓ PASSES

What these two standards are, and how they differ →

  • Business activity Its core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
  • Debt load Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. Fail
  • Interest-bearing cash Interest-bearing cash and securities are of assets, above the one-third limit. Fail
  • Receivables Money owed to the company is of assets, above the 49% limit. Fail
  • Revenue purity Only 0.0% of revenue comes from non-compliant sources — under the 5% line. Pass

Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.

The business, in plain words · what the numbers mean

Heart valves alone do not make a bargain

Picture a surgeon fitting an On-X valve into a patient. The procedure saves a life, yet the business behind it earns just three pence on every pound of sales while returning only three percent on equity. Artivion grows revenue at eighteen percent, yet trades at thirty-five times forward earnings with an unknown competitive moat. Those figures leave no margin for error once growth slows.

We pass because the seventeen percent gap between the twenty-five dollar share price and our twenty-nine dollar fair value does not compensate for thin profitability and an elevated multiple. Analyst targets sit higher, yet our screen finds nothing compelling once the low returns and high valuation are weighed together. Ethical clearance removes one objection but creates no investment case on its own.

Low margins leave little room for execution slips or reimbursement pressure, and an unknown moat offers scant protection if larger device makers expand. The combination keeps the opportunity rating at none despite the clean ethical screen. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E34.8x
priced for continued growth
Trailing P/E100.2x
expensive — the price assumes strong growth ahead
Revenue growth17.5%
steady growth
Profit margin2.5%
barely profitable
Return on equity3.1%
a modest return on shareholder capital
Debt to equity0.57
moderate, manageable leverage
Current ratio3.86
comfortably covers its short-term bills
Beta1.25
moves a little more than the market
Market cap$1.2B
Employees1,800

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.

Plain-English interpretation of our own screen data. Analysis, not advice.

Related securities · others in AORT's space worth a look

Screened names in the same industry · explore each on its own page.

Where & how to trade · wherever in the world you are

AORT trades on the NYSE. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The trader read · the latest dated commentary

The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 24.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (8 analysts) rates it strong buy, with a mean price target of $42. Entered 2026-07-21 · Distribution

The dated journal · newest first, never edited

2026-07-21 Distribution $25.06 +24.7% Entry 5

The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 24.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (8 analysts) rates it strong buy, with a mean price target of $42.

2026-07-18 Distribution $20.10 +0.0% Entry 4

The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (8 analysts) rates it strong buy, with a mean price target of $42.

2026-07-17 Distribution $20.10 +0.0% Entry 3

The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (8 analysts) rates it strong buy, with a mean price target of $42.

2026-07-03 Distribution $20.10 +0.0% Entry 2

The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.

2026-07-02 Distribution $20.10 Entry 1

The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

What holding actually paid · price plus dividends

If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $23.81 -14.0% · $860 -14.0%
2 months $37.63 -45.6% · $544 -45.6%
3 months $36.17 -43.4% · $566 -43.4%
6 months $45.48 -55.0% · $450 -55.0%
1 year $29.24 -30.0% · $700 -30.0%
2 years $23.27 -12.0% · $880 -12.0%
3 years $15.49 +32.2% · $1,322 +32.2%
5 years $29.06 -29.6% · $704 -29.6%

Historical returns from market close data. Past performance does not guarantee future results.

This entry now belongs to the ledger. Whatever AORT does next, these words stay.

Artivion, Inc. · AORT · Markup · $25.06
Recorded 2026-07-19 · before the outcome · scored mechanically

Get our weekly market brief free.